DOCSLIB.ORG

Science Industry Public Policy Economic Development the Future

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Science Industry Public Policy Economic Development the Future 2013-2014 Colorado by the Numbers Science Bioscience Industry Discovery Public Policy Evaluation Grant Economic Development Program The Future An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to off ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com Litho in U.S.A. 13_0280 JJ/KJ 13_0280 Colorado BioScience Ad.indd 1 2/21/2013 12:39:53 PM TABLE OF CONTENTS Welcome to the Colorado BioScience Association’s tenth anniversary edition of Bioscience Colorado, 10 years of supporting the the state’s only in-depth bioscience industry in Colorado guide and directory to the bioscience industry. In honor Then, Now, The Future of our 10 years supporting the bioscience industry in Colorado, we will be celebrating our successful history and looking ahead to the future. 5 16 Over the past decade, the Association has The Science The Economic grown from a small startup enterprise to a mature A Decade of Dramatic Development and successful organization. This publication Developments: Building the Colorado is an integral part of the Association’s mission Bioscience in Colorado Bioscience Industry to support the Colorado bioscience community Cluster: through advocacy, resources and advancement of opportunities for collaboration. With a 8 A Remarkable total audience of over 15,000, including on- The Industry Success Story line impressions, this publication is one of the Colorado Bioscience: industry’s greatest voices locally, nationally and A Microcosm of 20 internationally. Broader Industry The Future In this issue of Bioscience Colorado we look at the entire bioscience ecosystem in the state. The Trends The Next 10 Years: articles examine elements that are meant to infuse Peering into scientific excitement, highlight the success of 12 Bioscience’s policy partnerships—both locally and nationally— The Public Policy Crystal Ball as well as milestones, and showcase the evolution Partners for Progress: of Colorado’s industry from one well below the Three Colorado national rankings to a cluster rising to the top 10. 28 We know that Colorado is on the edge of Governors & Their Colorado by the creating a critical mass. With some of the Commitment to Numbers top research institutions in the U.S., over 600 Bioscience bioscience companies, and employment growth 32 outpacing the nation we are energized by the Looking Back Bioscience Discovery momentum. Given the collaborative nature of Colorado, our researchers, leaders, entrepreneurs at 10 Years of Policy Evaluation Grant and companies are committed to our success. Milestones Program We look forward to serving the industry and (BDEGP) working with the bioscience community for the next 10 years. Produced by: Published by: Colorado BioScience Association Colorado BioScience Association and April Giles 216 16th Street, Suite 850 Colorado Office of President and CEO Denver, CO 80202 Economic Development Colorado BioScience Association www.CoBioScience.com and International Trade (303) 592-4073 Advancing Biomedicine in Colorado The Anschutz Medical Campus and Fitzsimons Life Science District in Aurora is the nation’s newest health sciences city, integrating education, research (more than 1,100 research faculty and more than 2,500 researchers) and the best in clinical care (with three affiliated hospitals). In Boulder, the new Jennie Smoly Caruthers Biotechnology Building houses more than 600 faculty, staff and students from six CU- Boulder departments, helping create genuinely groundbreaking biotechnology research via the CU BioFrontiers Institute: a collaboration among CU-Boulder, the CU Anschutz Medical Campus and the University of Colorado Colorado Springs. CU is recruiting world-class interdisciplinary faculty for these and other initiatives, like the new Anschutz Center for Health and Wellness and the Department of Bioengineering at the Anschutz Medical Campus, and ongoing bioscience and technology efforts on the Boulder campus. CU has a track record of alliances with companies that enhance healthcare outcomes – CU research has led to four new approved drugs and numerous new diagnostic tests and medical devices, and CU is nationally prominent for new company creation, including biotech firms like Myogen (purchased by Gilead), GlobeImmune, ARCA biopharma, OPX Biotechnologies, SomaLogic, Taligen (purchased by Alexion) and over 70 others since 1994. CU Denver | Anschutz $500M Medical Campus Bio-related sponsored research funding Strategic Research Initiatives Laura Simon, 303.724.4636 received annually by CU’s four campuses. FDA-approved drugs developed at CU: Kineret, Macugen, Zostavax 4 and Botox (use). Connect with 200 biotech at CU Drugs, diagnostics and devices in CU’s active intellectual CU-Boulder New drugsNew in being tested 800 clinical trialsclinical by CU faculty property portfolio. BioFrontiers Institute Jana Watson-Capps, 303.492.3588 http://biofrontiers.colorado.edu Biotech companies founded based on CU 80 technologies, since 1994. CU technologies currently licensed Technology Transfer to bio industry CU Denver|Anschutz: Rick Silva, 303.724.0222 partners 155 CU-Boulder, UCCS: Kate Tallman, 303.492.5732 www.cu.edu/techtransfer A Decade of Dramatic Developments: Bioscience in Colorado BY ANDREA PAWLICZEK hink back to 2003. You may have just purchased your first cell phone with a camera. If you wanted to get in touch with a college friend or former colleague Tyou had to send an email or pick up the phone as Facebook was not online yet. For many of us, looking back at the use of personal technology may be the easiest way to see major developments over the last 10 years, but the changes that have affected scientific research are just as dramatic—and in some ways similar. THE HUMAN GENOME AND PERSONALIZED MEDICINE The human genome project, which aimed to sequence the entire human genome—our full set of chromosomes—was initiated in 1990. In April 2003, the project announced that sequencing was essentially complete (a first draft was done in 2001), two years ahead of schedule. Understanding the human body at a genetic level has greatly influenced research to identify specific cellular pathways or confirm this over-expression before treatment and treatment of disease over the past decade mutations, create targeted therapies that may is initiated. This idea of not just considering as researchers have begun to inhibit a specific pathway, and develop feasible cancer by location or organ system, but also put this knowledge to use. tests to identify patients with particular by genetic profile has become increasingly Stuart Tobet, professor in the markers. The hopes that have begun to be important as the number of targeted cancer Department of Biomedical realized are that personalizing treatment will therapies (treatments that target specific Sciences at Colorado State make it both more efficient and effective. pathways) has exploded over the last 10 years. University, notes “Personalized The evolution of personalized medicine Dr. Paul Bunn, James Dudley Chair in medicine is a major trend that began with is perhaps most evident in the treatment of Cancer Research at the University of Colorado the sequencing of the genome.” Treatments cancer. Herceptin® (trastuzumab), approved Denver School of Medicine, notes that “There currently under investigation are developed by the FDA in 1998, was one of the first is definitely an opportunity for diagnostic specifically for groups of patients with drugs to be recommended for patients based companies,” who can develop companion particular genotypes or protein markers. on genetics. Specifically, Herceptin is only diagnostics for specific biomarkers that This work encompasses several non-trivial effective in patients with over-expression of identify the patients most likely to benefit from milestones from basic scientific research the HER2 gene, and thus patients are tested to a particular therapeutic. BIOSCIENCE COLORADO 2013/2014 5 “Some of the research we want to do on live tissue would generate gigabits of data per second, and that sort of bandwidth is not that far away.” As our understanding of how cells and systems work improves, the opportunity for different types of treatments beyond small molecules that act broadly on major systems emerges. Bunn sees both “the use of cell therapy and manipulated cells and immune GROWING collaboration ACROSS therapies” as emerging areas that are likely DISCIPLINES to continue to increase in importance over With an increased knowledge base has the next several years. Cell therapies, which also come increased complexity, making it actually use living cells as treatment, and less likely that any one individual, or even immune therapies, which may activate or one department, possesses all the information suppress a patient’s immune system to fight or skills needed for significant advances a disease, require a greater understanding in research. Consequently, collaborative of how individual cells work and the
Load more

Recommended publications
  • Ulcerative Colitis
    +44 20 8123 2220 [email protected] Ulcerative Colitis - Pipeline Review, H1 2020 https://marketpublishers.com/r/U44188EFA0EEN.html Date: April 2020 Pages: 671 Price: US$ 2,000.00 (Single User License) ID: U44188EFA0EEN Abstracts Ulcerative Colitis - Pipeline Review, H1 2020 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids. REPORT HIGHLIGHTS Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players Ulcerative Colitis - Pipeline Review, H1 2020 +44 20 8123 2220 [email protected] involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects.
    [Show full text]
  • Kansas City Regional Life Sciences Industry Census 2018 Executive Summary
    Kansas City Regional Life Sciences Industry Census 2018 Executive Summary ................................................................................................................... 4 Background ................................................................................................................................ 7 Methodology .............................................................................................................................. 8 Industry Presence, Overview & Analysis ...................................................................................12 Introduction ...........................................................................................................................12 Presence and Overview ........................................................................................................13 Regional Developments 2016-2018 ...................................................................................13 Life Sciences Capital .........................................................................................................21 Incubators, Accelerators, and New Business Facilities.......................................................25 Universities ........................................................................................................................28 Hospitals ............................................................................................................................32 Analysis .................................................................................................................................33
    [Show full text]
  • Life Science District
    Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing. unique opportunities for business Pharmaceuticals. And with Denver Which means the opportunities for development. The University’s International Airport being only 15 improvement—in the health of Technology Transfer o ce, ranked minutes away, access to both coasts Coloradoans and in the health of among the top 20 universities for takes only a few hours.
    [Show full text]
  • Ensuring U.S. Biopharmaceutical Competitiveness
    Ensuring U.S. Biopharmaceutical Competitiveness STEPHEN EZELL | JULY 2020 If the United States is serious about maintaining its leadership in biopharmaceuticals, then it’s time for policymakers to articulate and embrace a robust sectoral competitiveness strategy. KEY TAKEAWAYS ▪ The biopharmaceutical industry makes important contributions to the U.S. economy, including employing over 500,000 workers making 1.4 times the U.S. earnings average. ▪ The United States leads the world on most indices of R&D investment and innovation. From 2004 to 2018, U.S.-headquartered firms produced almost twice as many new drugs as did firms in Europe, and 3 to 4 times as many as Japan. ▪ Despite U.S. strengths in biopharmaceutical R&D and innovation, manufacturing has dropped. From 2009 to 2018, real value-added output in pharmaceutical and medicines manufacturing fell by nearly one-third. ▪ Partly as a consequence, the U.S. trade balance in pharmaceuticals has grown from a deficit of $16 billion in 2010 to a deficit of $77 billion in 2019. ▪ Calls for reshoring more biopharmaceutical manufacturing should distinguish between mature manufacturing processes and those still evolving, as in continuous process biomanufacturing, where U.S.-based production can enjoy unique strengths. ▪ America must continually bolster its biopharmaceutical leadership position, especially as China implements ever-more aggressive policies to improve their life-sciences competitiveness, not only in production but also in innovation. ▪ To support the sector, policymakers should focus on: 1) maintaining strengths, including in pricing, tech transfer, and intellectual property; 2) spurring domestic innovation; 3) spurring increased domestic production; and 4) combatting foreign mercantilism.
    [Show full text]
  • An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
    An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to o ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com 2 BIOSCIENCECOLORADO 2014-2015 Litho in U.S.A. 13_0280 JJ/KJ COLOR ADO 2014-2015 Drawing People & Data Together to Benefit Human Health 10 22 26 14 6 CONTENTS 06 Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 10 Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 14 Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 16 Color ado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 22 Webb-Waring Biomedical Research Program 26 F ound in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 30 Connecting the Dots: Tech Transfer Offices Connect Research and Marketplace to Stimulate the State's Economy 33 Colorado by the Numbers: Financing and Acquisitions 36 Grant Programs: Innovation Engines 48 Colorado Bioscience Industry Directory 2014-2015 BIOSCIENCECOLORADO 3 We Know Workforce elcome to the Colorado BioScience Association’s eleventh anniversary edition of Bioscience Colorado.
    [Show full text]
  • Biotecnología Y Desarrollo
    Documento de proyecto Biotecnología y desarrollo Roberto Bisang Mercedes Campi Verónica Cesa Comisión Económica para América Latina y el Caribe (CEPAL) Este documento fue preparado por Roberto Bisang y Verónica Cesa, consultores, y Mercedes Campi, asistente de investigación de la Oficina de la Comisión Económica para América Latina y el Caribe (CEPAL) en Buenos Aires a pedido de la Oficina de la Secretaría Ejecutiva de la CEPAL. Las opiniones expresadas en este documento, que no ha sido sometido a revisión editorial, son de exclusiva responsabilidad de los autores y pueden no coincidir con las de la Organización. Publicación de las Naciones Unidas LC/W.234 LC/BUE/W.35 Copyright © Naciones Unidas, marzo del 2009. Todos los derechos reservados Impreso en Naciones Unidas, Santiago de Chile La autorización para reproducir total o parcialmente esta obra debe solicitarse al Secretario de la Junta de Publicaciones, Sede de las Naciones Unidas, Nueva York, N. Y. 10017, Estados Unidos. Los Estados miembros y sus instituciones gubernamentales pueden reproducir esta obra sin autorización previa. Sólo se les solicita que mencionen la fuente e informen a las Naciones Unidas de tal reproducción. CEPAL – Colección Documentos de proyectos Biotecnología y desarrollo Índice Resumen .................................................................................................................................. 5 I. Introducción ............................................................................................................................
    [Show full text]
  • Framing the Genetic Engineering Debate: an Examination of Frames and Sources in Local Newspaper Reporting
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2005 Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting Catherine Emma Crawley University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Communication Commons Recommended Citation Crawley, Catherine Emma, "Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting. " PhD diss., University of Tennessee, 2005. https://trace.tennessee.edu/utk_graddiss/1907 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Catherine Emma Crawley entitled "Framing the Genetic Engineering Debate: An Examination of Frames and Sources in Local Newspaper Reporting." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Communication and Information. Edward Caudill, Major Professor We have read this dissertation and recommend its acceptance: Paul Ashdown, Suzanne
    [Show full text]
  • Warhawk Therapeutic Technologies
    New Product Assessment Warhawk Therapeutic Technologies Therapeutic proteins are proteins that are either engineered in a laboratory or extracted from human or animal cells for pharmaceutical use as the active substance in a drug. Most of these therapeutic proteins are recombinant human proteins. They are manufactured in non-human mammalian cell lines that have been designed to express a specific human genetic sequence. The majority of these biopharmaceuticals are recombinant therapeutic proteins administered by injection. Once injected into the body, the proteins are broken down by enzymes and cellular activity in the bloodstream and are filtered out of the blood by the body’s organs. Thus, patients must receive frequent injections to maintain effective therapeutic levels of protein in the body. Therapeutic proteins are used for treatment and prevention of diseases and disorders in the human body. For example diabetes, arthritis, infections, heart attacks, and cancers can all be treated through the use of these proteins. There are several production technologies in this industry aimed at maximizing the production yields of these proteins. Current methods of production only yield 10 percent to 20 percent of the therapeutic proteins. However, Warhawk Therapeutic Technologies’ production technology is capable of yielding XX – XX percent which, in turn will reduce production costs and initial capital investments on manufacturing facilities. Additionally, the protein folding process employed by Warhawk Therapeutic Technologies does not require the use of strong chemical reagents or special equipment. The following report includes a review of competition, a preliminary patent search, a sample of market feedback, and an investigation into trends that may affect the market for the Warhawk Therapeutic Technologies protein folding system.
    [Show full text]
  • Biotechnology Training Retreat
    3333 Eighteenth Annual Biotechnology Training Retreat Saturday, March 29, 2008 Christian Brothers Retreat & Conference Center Napa, CA Eighteenth Annual Biotechnology Training Retreat Saturday, April 4, 2009 Christian Brothers Retreat & Conference Center Napa, CA Co-sponsored by: NIH Training Program in Biomolecular Technology (NIH-1-T32-GM08799) UC Davis Designated Emphasis in Biotechnology Graduate Program (DEB) UC Davis Biotechnology Program 2 Table of Contents Welcome .............................................................................................................................. 4 NIH Training Program in Biomolecular Technology ................................................................. 6 Designated Emphasis in Biotechnology, UC Davis ............................................................. 7 UC Davis Biotechnology Program ...................................................................................... 8 Retreat Agenda .................................................................................................................... 9 2009 Poster Titles ............................................................................................................. 10 Oral Presentation Abstracts ............................................................................................... 14 Bioethics ........................................................................................................................... 35 Poster Abstracts ................................................................................................................
    [Show full text]
  • Bridging the Gap: from Discovery to Commercialization
    Bridging the Gap: from Discovery to Commercialization Bioscience Discovery Visualizing Evaluation the Gap Grant Program page 6 page 24 Colorado by Directory the Numbers: of Bioscience 2011 update Companies and page 11 Resources page 42 Fitzsimons Life Science District a great place to raise an idea Located in Aurora, Colorado, it’s one of the largest bioscience developments in the country, a place where there’s plenty of room to grow an idea from discovery to market viability. Whether you start in the bioscience incubator or move into a state-of-the art lab facility, everything you need is close at hand. A cluster of talent and resources is available to you, including direct access to the more than 80 core laboratories at the University of Colorado Anschutz Medical Campus – all just steps away. Features throughout the district, such as parks and conference facilities, are designed to inspire collaboration. And a nearby mix of shops, restaurants and homes let your people thrive right along with your ideas. For leasing and land purchase opportunities at the Colorado Science + Technology Park, within the Fitzsimons Life Science District, call 720-941-7100. Join the conversation at FitzScience.com FIT 110352 Brand Ad_M.indd 1 3/23/11 1:32 PM Improve the health of your business. Collaborations between bioscience 227 acres of state-of-the-art patient successful Colorado companies such companies and faculty researchers at care, research and education, the as Myogen/ Gilead Sciences Colorado, the University of Colorado Anschutz Anschutz Medical Campus provides GlobeImmune, ARCA, and ApopLogic Medical Campus are flourishing.
    [Show full text]
  • Directory Sequel Ventures of Colorado Sierra Neuropharmaceuticals Bioscience Taligen Therapeutics Companies Page 6
    The Money Game Hear From Barofold ARCA Biopharma Directory Sequel Ventures of Colorado Sierra Neuropharmaceuticals Bioscience Taligen Therapeutics Companies Page 6 & Resources Page 38 Colorado’s Bioscience Industry By the Numbers Page 12 Colorado Invests In the Biosciences Page 33 DPMPSBEP TDJFODF $PMMBCPSBUJPOCSFFETJOOPWBUJPO UFDIOPMPHZ QBSL BU¾U[TJNPOT $PMMBCPSBUJPOCSFFETJOOPWBUJPO°BOE JOOPWBUJPOCFDPNFTTPMVUJPOTBOEDVSFT 5IF$PMPSBEP4DJFODF 5FDIOPMPHZ1BSL BU'JU[TJNPOTJTQFSGFDUMZQPTJUJPOFEUP DPMMBCPSBUFXJUIUIFBEKBDFOU6OJWFSTJUZ PG$PMPSBEPµT"OTDIVU[.FEJDBM$BNQVT BOE5IF$IJMESFOµT)PTQJUBM*OGBDU DPMMBCPSBUJPO DPPQFSBUJPOBOETDJFOUJ¾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µT)PTQJUBM 5)&$)*-%3&/µ4)041*5"- JTEF¾OJUFMZUIFDBUBMZTUGPSUIJTTVDDFTTGVM "/%3&4&"3$)$&/5&3 TDJFOUJ¾DGPSNVMB 5IF$PMPSBEP4DJFODF 5FDIOPMPHZ1BSLBU 'JU[TJNPOTJTBQMBDFXIFSFUIFCFTUBOEUIF CSJHIUFTUDPNFUPHFUIFSUPUBLFJEFBTGSPN CFODIUPCFETJEFBQMBDFXIFSFDSFBUJWJUZ BOEDPMMBCPSBUJPOSFBDIDSJUJDBMNBTT XXX'JU[4DJFODFDPN cstp-f ad_f.indd 1 3/21/08 10:15:13 AM #JPTDJFODF$PMPSBEP.BHB[JOF QBHF4QSFBEY CMFFE $PMPSBEP4DJFODF
    [Show full text]
  • Enabling Innovation We’Re Proud to Partner with Colorado Bioscience Association to Bring You More Than 1.7 Million Laboratory and Research Products
    2019 - 2020 Enabling Innovation We’re proud to partner with Colorado Bioscience Association to bring you more than 1.7 million laboratory and research products. You’ll find a full range of antibodies, reagents, and other life sciences materials, including exclusive Applied Biosystems™ and Invitrogen™ products. Plus, take advantage of cost savings, incentives, and value-added services available through the Fisher Scientific channel. We’re proud to be your exclusive partner for: Lab essentials, supplies, and equipment R&D collaboration Scientific instruments Clinical trial support Encompass Procurement Services Production efficiencies Supply chain optimization Life sciences tools Visit cobioscience.com to learn more. ISORDERS 8 NTESTINAL 39 ISORDERS 36 X HORMONES 31 ISORDERS 33 ISORDERS 16 UNOLOGY 111 S DISEASE 199 LE HEALTH 18 ISORDERS 172 ISORDERS 6 ISORDERS 55 ISORDERS 3 ISORDERS 8 2019-2020 2019 - 2020 2019 - // BIOSCIENCE COLORADO 3 We’re proud to work with our partners, across the state and nationally. We know innovation and advancement doesn’t happen without collaboration, and Colorado has demonstrated we are particularly good at boosting each other to positions where we all succeed. There is something different about Colorado. It’s more than our beautiful natural sur- roundings and abundant sunshine. It goes beyond You will find that in the unique approaches industry our favorable business climate and talented work- is innovating to address pain management beyond force. In Colorado, companies and organizations the traditional prescriptions. The problem is too share a commitment to working together and helping large for any one person to solve. But, working each other solve business challenges.
    [Show full text]